Clinical Trials Directory

Trials / Completed

CompletedNCT01202942

Use and Harm Exposure in New Low Nicotine Cigarettes

Smoking Topography and Harm Exposure in a New Potentially Reduced Exposure Product

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
246 (actual)
Sponsor
University of Pennsylvania · Academic / Other
Sex
All
Age
21 Years – 65 Years
Healthy volunteers
Accepted

Summary

The proposed research extends previous research on Quest® cigarette smoking behavior by testing whether compensatory smoking occurs as cigarette nicotine level decreases, and whether, as a result, biomarkers of harm exposure increase. This hypothesis will be tested in 210 smokers who report smoking at least 15 cigarettes per day and have been smoking for at least five years and are not currently interested in quitting, but interested in trying a new cigarette product. Participants will be randomized to one of three conditions: 1) smoke their own preferred brand (control group); 2) smoke Quest® cigarettes in progressively decreasing cigarette nicotine level (step-down); or 3) Quest® cigarette non-step-down condition, where they will smoke Quest® cigarettes in a random order. The study will consist of 4 stages beginning with a 5-day preferred own brand cigarette smoking phase for all participants, followed by one of the three cigarette conditions. For those smoking Quest® cigarettes, cigarette nicotine level will change every 10 days, either in a step-down or random fashion. The primary behavioral outcome is smoking topography, a quantitative measurement of smoke exposure. Alveolar carbon monoxide (CO), a validated assessment of smoke exposure, and urine samples to assess carcinogen exposure, specifically NNAL (4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol) and 1-HOP (1-hydroxypyrere), and exhaled breath condensate will also be collected at the laboratory visits. At the initiation of the study, participants will view the Quest® print advertisement and complete a survey related to product expectations in order to determine the impact marketing and advertisement has on beliefs, attitudes and behaviors related to Quest® cigarettes.

Conditions

Interventions

TypeNameDescription
OTHERQuestParticipants smoke Quest cigarettes level 1 for 10 days, level 2 for 10 days, level 3 for 10 days.

Timeline

Start date
2007-07-01
Primary completion
2013-05-01
Completion
2013-06-01
First posted
2010-09-16
Last updated
2013-12-19

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT01202942. Inclusion in this directory is not an endorsement.